Fate Therapeutics Inc (FATE)
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune disorders in the United States and other international markets. Its pipeline includes CAR-targeted NK and T-cell product candidates such as FT836, which is in preclinical development for multiple tumor types, and FT522, which is being developed for B-cell lymphoma and autoimmune disease. The company’s CAR T-cell programs include FT819 for systemic lupus erythematosus, FT839 for complex autoimmune diseases, and FT825 for solid tumors. Fate Therapeutics also has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. covering off-the-shelf, iPSC-derived CAR T-cell candidates for solid tumors. Incorporated in 2007, the company is based in San Diego, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-FATE
|
$2.63
|
-7.3% Downside
|
Fair
|
$5.41
|
90.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
-2.5x
|
1.8x
|
51.9x
|
325.8 M
|
230.1 M
|
19.1%
|
87.4%
|
-6.8
|
—
|
83.2%
|
